HOME
ABOUT US
Company Profile
Management Team
Corporate Culture
SAB
Milestones
R & D
Pipeline
Areas of Focus
Strategy
NEWS CENTER
News Center
PARTNERS
Partners
INVESTORS
Investors
CAREERS
Join Us
Employee Benefits
CONTACT
Contact
中文|EN
Company Profile
ABOUT US
Guangdong Raynovent Biotech Co., Ltd. ("Raynovent") is a biotech company specializing in the R&D and commercialization of innovative drugs for respiratory and metabolic diseases. Founded in October 2018, the company is headquartered in Huangpu District, Guangzhou, China.
READ MORE
NEWS CENTER
Leritrelvir Tablets (Brand Name: 乐睿灵®) Receive Regular Approval from NMPA: A Leap from Conditional to Full Market Authorization
Leritrelvir Tablets (Brand Name: 乐睿灵®) Receive Regular Approval from NMPA: A Leap from Conditional to Full Market Authorization
2026/08/25 News Center
2026 ADA Oral Presentation | Raynovent RAY1225 Injection Phase II Study Shines: Up to 21.2% Weight Loss at 24 Weeks
2026 ADA Oral Presentation | Raynovent RAY1225 Injection Phase II Study Shines: Up to 21.2% Weight Loss at 24 Weeks
2026/06/08 News Center
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatoh
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2026/05/08 News Center
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
2026/05/06 News Center
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
2026/05/06 News Center
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026/05/06 News Center
Leritrelvir Tablets (Brand Name: 乐睿灵®) Receive Regular Approval from NMPA: A Leap from Conditional to Full Market Authorization
Leritrelvir Tablets (Brand Name: 乐睿灵®) Receive Regular Approval from NMPA: A Leap from Conditional to Full Market Authorization
2026/08/25 News Center
2026 ADA Oral Presentation | Raynovent RAY1225 Injection Phase II Study Shines: Up to 21.2% Weight Loss at 24 Weeks
2026 ADA Oral Presentation | Raynovent RAY1225 Injection Phase II Study Shines: Up to 21.2% Weight Loss at 24 Weeks
2026/06/08 News Center
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatoh
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2026/05/08 News Center
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
2026/05/06 News Center
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
2026/05/06 News Center
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026/05/06 News Center
JOIN US
Application To: HR@Raynovent.com
Looking forward to your joining!